Efficacy of Colesevelam in Subjects With Type 1 Diabetes Mellitus
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
This is a prospective, randomized, double blind, parallel, placebo controlled clinical trial
evaluating the efficacy of colesevelam HCl in reducing LDL in subjects with type 1 diabetes
mellitus over a 12 week treatment period. The aim is to highlight the effect of colesevelam
on LDL cholesterol and glycemia in a type 1 diabetic population. The colesevelam group is
anticipated to demonstrate a mean reduction in LDL by 10% compared to the placebo group,
indicated by A1c and glycemic target range CGM readings.
Phase:
N/A
Details
Lead Sponsor:
University of Colorado Denver School of Medicine Barbara Davis Center